The hippocampus plays an important role in emotional and cognitive processing, and both
of these domains are affected in patients with major depressive disorder (MDD). Extensive …

… CK has received grant funding from Lundbeck as well as honoraria and consultancy fees
from Lundbeck, Lilly, Pfizer-Eisai and Novartis. TH and CKO are employees of Lundbeck. H. …

The efficacy of vortioxetine 10 and 20 mg/d vs. placebo on cognitive function and depression
in adults with recurrent moderate-to-severe major depressive disorder (MDD) was …

Background Tralokinumab is a fully human monoclonal antibody that specifically neutralizes
interleukin‐13, a key driver of atopic dermatitis (AD). Objectives To evaluate the efficacy …

This study assessed the efficacy, tolerability and safety of vortioxetine versus placebo in
adults with recurrent major depressive disorder. This double-blind, randomized, placebo-…

Background: Management of cognitive deficits in Major Depressive Disorder (MDD) remains
an important unmet need. This meta-analysis evaluated the effects of vortioxetine on …

Background Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds
with high affinity to interleukin‐13, effectively reduces moderate‐to‐severe atopic dermatitis (…

Cognitive dysfunction is common in depression during both acute episodes and remission.
Vortioxetine is a novel multimodal antidepressant that has improved cognitive function …

IL-6 is secreted from muscles to the circulation during high-intensity and long-duration
exercise, where muscle-derived IL-6 works as an energy sensor to increase release of energy …

Background Tralokinumab is a fully human monoclonal antibody that neutralizes the activity
of interleukin‐13, a key pathogenic driver of atopic dermatitis (AD). Clinical trials including …